Rasmussen Encephalitis

Status: draft · Last updated 2026-11-17 · By Jason S. Hauptman, MD, PhD (AI-assisted)

Read in the interactive book →

High-yield points

  • RE = immune-mediated, unihemispheric, progressive. Atrophy, deficits and drug-resistant focal seizures (often epilepsia partialis continua), mostly in children .
  • MRI: progressive unilateral perisylvian and insular atrophy with caudate head atrophy (see caveats).
  • Tacrolimus or IVIG may slow early disease (compared with historical controls) but does not rescue established drug-resistant epilepsy .
  • Hemispherotomy is definitive: 68% seizure-free, with function largely preserved, including in left-hemisphere cases .

Landmark papers

  • Bien et al., Epilepsia 2013: the first (and still the only) randomized trial in Rasmussen encephalitis (16 patients with recent-onset disease, tacrolimus or IVIG). Both groups did better than historical controls and neither drug was better; no patient with already refractory epilepsy responded .

Rasmussen encephalitis (RE) is a rare, severe, immune-mediated disease of one hemisphere. It causes three things together :

Hemispheric disconnection is the treatment of choice for established disease. The difficult decision is when to operate .

Jason S. Hauptman, MD, PhD© 2026 Jason S. Hauptman, MD, PhD. All rights reserved. Original figure from Hauptman's High Yield Thoughts in Pediatric Neurosurgery (pedsneurosurg.org). Do not copy, reproduce, redistribute or adapt without written permission.https://www.pedsneurosurg.org/hy-peds-ns:rasmussen:94f262e75a359753© 2026 Jason S. Hauptman, MD, PhD. All rights reserved. Original figure; please do not copy, reproduce or redistribute without written permission.Three serial coronal FLAIR-style images showing progressive unilateral perisylvian and insular atrophy, caudate head atrophy and cortical hyperintensity with a normal opposite side; histology with T cells around a neuron, a microglial nodule and neuronophagia; and a decision strip from immunotherapy to functional hemispherotomy(A) SERIAL CORONAL FLAIR: PROGRESSIVE UNILATERAL ATROPHYONSETMONTHSYEARSFLAIR cortexinsular atrophycaudate atrophynormal side(B) HISTOLOGY (SCHEMATIC)cytotoxic (CD8) T cellsaround a neuronmicroglial noduleneuronophagiamicroglia engulf a dying neuron(C) DECISIONearly disease or preserved functionimmunotherapy (tacrolimus, IVIG) to slow progressionestablished deficit and drug-resistant epilepsyfunctional hemispherotomy68% seizure-free after hemispheric surgery
Rasmussen encephalitis. (a) Serial axial or coronal MRI: progressive atrophy of one hemisphere beginning in the perisylvian/insular region, with caudate head atrophy and cortical T2/FLAIR hyperintensity, sparing the opposite side. (b) Histology schematic: cytotoxic T cells against neurons, microglial nodules and neuronophagia. (c) Course and decision: early immunotherapy (tacrolimus, IVIG) may slow progression; once deficits and drug-resistant epilepsy are established, functional hemispherotomy. Not to scale.

Epidemiology and pathogenesis

Diagnosis (European consensus criteria)

Treatment

Immunotherapy

Hemispheric surgery

Related topics

References

  1. Bien CG, Granata T, Antozzi C, et al. Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: a European consensus statement. Brain 2005;128(Pt 3):454–471. doi:10.1093/brain/awh415. PMID 15689357. verified
  2. Bien CG, Tiemeier H, Sassen R, et al. Rasmussen encephalitis: incidence and course under randomized therapy with tacrolimus or intravenous immunoglobulins. Epilepsia 2013;54(3):543–550. doi:10.1111/epi.12042. PMID 23216622. verified
  3. Thomé U, Batista LA, Rocha RP, et al. The important role of hemispherotomy for Rasmussen encephalitis: clinical and functional outcomes. Pediatr Neurol 2024;150:82–90. doi:10.1016/j.pediatrneurol.2023.10.016. PMID 37992429. verified

Verification (2026-11-17):

Caveats: